IL7 and triple-negative breast carcinoma: A clinical trial of IL-7 and atezolizumab for the treatment of urothelial carcinoma (NCT03513952) is also ongoing, and IL-7-Fc is being used in combination with pembrolizumab in a clinical trial of triple-negative breast cancer [102].